Abstracts tagged "autoimmune diseases"

Abstract Number: 0988 • ACR Convergence 2024
Antinuclear Antibody Positivity and Its Diagnostic Implications for Rheumatic Diseases in Dermatology Patients: A Comprehensive Single Center Analysis
Yunjung Choi¹, Myeung-Su Lee² and Wan-Hee Yoo³, ¹Jeonbuk National University Medical School, Deokjin-gu, Jeollabuk-do, Republic of Korea, ²Wonkwang University Hospital, Iksan, South Korea, ³CHONBUK NATIONAL UNIVERSITY HOSPITAL, JEONJU, Republic of Korea
Background/Purpose: Cutaneous manifestations are common in rheumatic diseases and can be early indicators. This study investigates the prevalence of rheumatic diseases diagnosed through ANA (Antinuclear…
Abstract Number: 1141 • ACR Convergence 2024
Defining a Novel Type of Myositis: Immune Mediated Megaconial Myopathy (IMMM)
Teerin Liewluck¹, Ashley Santilli², Oliver Ni³, Margherita Milone², Duygu Selcen², Anahit Mehrabyan⁴, Arjun Seth⁵, Christine Hsieh⁵, Wasim Raslan⁶, Moayd Alkhalifah⁶, Raed Alenezi⁶, Stefan Nicolau⁷ and Pannathat Soontrapa⁸, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic-Rochester, Rochester, MN, ³Hennepin Healthcare, Minneapolis, MN, ⁴University of North Carolina, Chapel Hill, NC, ⁵Northwestern University, Chicago, IL, ⁶Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia, ⁷Nationwide Children’s Hospital, Columbus, OH, ⁸Siriraj Hospital, Mahidol University, Bangkok, Thailand
Background/Purpose: To describe a novel type of myositis, immune mediated megaconial myopathy (IMMM), pathologically characterized by giant mitochondria (megaconia).Methods: We reviewed the Mayo Clinic Muscle…
Abstract Number: 1420 • ACR Convergence 2024
Alignment Between Rheumatology and Neurology of Nomenclature for Peripheral Nervous System Neuropathies
Ghaith Noaiseh¹, George Sarka², Anahita Deboo³, Arun Varadhachary⁴, Robert Fox⁵, Matthew Baker⁶, Stamatina Danielides⁷, Eduardo de Sousa⁸, Julie Frantsve Hawley⁹, Brent Goodman¹⁰, Katherine Hammitt⁹, Jennifer King¹¹, Steven Mandel¹², Pantelis Pavlakis¹³, Daniel Wallace¹⁴, Robert Hal Scofield¹⁵, Nancy Carteron¹⁶ and Steven Carsons¹⁷, ¹University of Kansas Medical Center, Kansas City, KS, ²UCLA, Laguna Hills, CA, ³Temple University, Philadelphia, ⁴Washington University in St. Louis, St. Louis, MO, ⁵Rheumatology Clinic, San Diego, CA, ⁶Stanford University, Menlo Park, CA, ⁷Vcu, Glen Allen, VA, ⁸Mercy, Moore, OK, ⁹Sjogren's Foundation, Reston, VA, ¹⁰Mayo Clinic, Scottsdale, AZ, ¹¹UCLA, Los Angeles, CA, ¹²Hofstra, Hempstead, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Cedars Sinai Medical Center, Studio City, CA, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶University of California, Berkeley & San Francisco, Angwin, CA, ¹⁷NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: The Sjögren’s Foundation Clinical Practice Guidelines for Peripheral Nervous System (PNS) diagnosis, management and treatment in Sjögren’s brought to the fore a major issue…
Abstract Number: 1590 • ACR Convergence 2024
Milder ILD with Preserved Lung Function Significantly Contributes to Respiratory Caused Mortality in SSc
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim¹, Emily Langballe², Hilde Jenssen Bjørkekjær³, Henriette Didriksen¹, Phuong Phuong Diep⁴, Anna Helena Andersson¹, Ragnar Gunnarsson¹, Michael T Durheim¹, Torhild Garen¹, Øyvind Midtvedt⁵, Trond Mogens Aaløkken⁶, Øyvind Molberg⁷ and Oliver Distler⁸, ¹Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Kristiansand, Norway, ⁴Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, ⁵Oslo University Hospital, Oslo, Oslo, Norway, ⁶Medicine, Oslo, Norway, Oslo, Norway, ⁷Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). While impaired lung function with forced vital capacity (FVC) <…
Abstract Number: 1740 • ACR Convergence 2024
Performance of Large Language Models in Rheumatology Board-Like Questions: Accuracy, Quality, and Safety
Jaime Flores Gouyonnet¹, Mariana Gonzalez-Trevino¹, Cynthia Crowson¹, Ryan Lennon¹, Alain Sanchez-Rodriguez², Gabriel Figueroa-Parra³, Elena Joerns⁴, Bradly Kimbrough⁵, Maria Cuellar-Gutierrez¹, Erika Navarro-Mendoza¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Mayo Clinic, Rochester, ⁵Mayo Clinic Rochester, Rochester, MN
Background/Purpose: Large language models (LLMs) are increasingly becoming a common source of information for clinicians. We aimed to evaluate the accuracy, quality, and safety of…
Abstract Number: 1833 • ACR Convergence 2024
Immune Complexes of Antibodies Directed to Angiotensin Receptor type-1 and Extracellular Vesicles Are Unique Modulators Contributing to Systemic Sclerosis
Alexander Maximilian Hackel¹, Marieke Leiber¹, Maike Winziers¹, Gabriela Riemekasten² and Reza Akbarzadeh¹, ¹Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany, ²University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany
Background/Purpose: Antibodies (Abs) directed against the angiotensin II type-1 receptor (AT1R) and extracellular vesicles (EVs) derived from systemic sclerosis (SSc) patients have the potential to…
Abstract Number: 1927 • ACR Convergence 2024
Ethnic and Racial Minorities in Clinical Trials for Autoimmune Connective Tissue Disease Therapeutic Agents
Connor Buechler, Lindsey Wanberg, Cody Rasner, Nicole Theis-Mahon, Dawn Hackman and David Pearson, University of Minnesota, Minneapolis, MN
Background/Purpose: Black, Indigenous, and people of color (BIPOC) experience greater morbidity and mortality from autoimmune connective tissue diseases (AICTDs); thus, equitable access to randomized controlled…
Abstract Number: 2055 • ACR Convergence 2024
Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)
Laura Kopplin¹ and Karen Armbrust², ¹Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, ²Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN
Background/Purpose: Scleritis is a rare, potentially vision threatening ocular inflammatory disease. 30-40% of scleritis is associated with systemic autoimmune diseases with reports of worse visual…
Abstract Number: 2326 • ACR Convergence 2024
Development and Evaluation of a Machine Learning Model for the Early Identification of Psoriatic Arthritis
Michael Dreyfuss¹, Dan Riesel², Guy Shalev², Benjamin Getz³, Or Ramni², Yonatan Jenudi⁴, Dimid Duchovny², Daniel Underberger⁵, Shlomit Steinberg-Koch², Douglas White⁶ and Elena Myasoedova⁷, ¹Predicta Med, Ramat Gan, Israel, ²Predicta Med Analytics Ltd., Ramat Gan, Israel, ³CTO, Ramat Gan, Israel, ⁴[email protected], Ramat Gan, Israel, ⁵Predicta Med Analytics Ltd., Bridgeport, CT, ⁶Gundersen Health System, Onalaska, WI, ⁷Mayo Clinic, Rochester, MN
Background/Purpose: Delays in diagnosis of psoriatic arthritis (PsA) are associated with indolent and non-specific signs and symptoms, and often result in physical impairment and poorer…
Abstract Number: 2503 • ACR Convergence 2024
Hypothalamic-Pituitary-Adrenal Axis Suppression by Prednisolone Reversed by the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Clofutriben
Frank S Czerwiec¹, Irina Bancos², Paul M Stewart³, Ketan Desai¹ and David A Katz¹, ¹Sparrow Pharmaceuticals, Portland, OR, ²Mayo Clinic, Rochester, MN, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Approximately 1% of the population rely on chronic glucocorticoid (GC) prescription to control autoimmune and inflammatory conditions. Risk of GC induced adrenal insufficiency (GC-AI)…
Abstract Number: 2615 • ACR Convergence 2024
Prevalence of and Factors Associated with Developing Long COVID Among Patients with Autoimmune Rheumatic Diseases: A Retrospective Cohort Analysis of National U.S. Data
Namrata Singh¹, Jerrod Anzalone², Lesley Jackson³, Sandra Safo⁴, Zachary Butzin-Dozier⁵, Kaleb Michaud⁶, Holland Stevenson⁶, Maria I. ("Maio") Danila⁷, Jasvinder Singh⁸ and Rena Patel⁹, ¹University of Washington, Bellevue, WA, ²University of Nebraska Medical Center, Omaha, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Minnesota, Minneapolis, MN, ⁵University of California Berkeley School of Public Health, Berkeley, CA, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ⁸Baylor College of Medicine, Birmingham, AL, ⁹University of Alabama at Birmingham, Birmingham
Background/Purpose: Patients with Autoimmune Rheumatic Diseases (AIRDs) are at higher risk of severe COVID-19 outcomes, with greater risk among those with multiple comorbidities, using specific…
Abstract Number: 0086 • ACR Convergence 2024
Evaluating the Efficacyof B Cell Targeting Drug Candidates Using a Humanized BAFF Transgenic SLE Mouse Model
Juan Liang, Shuxin Xu, Qiuping Xu and Yuxi Zhang, GemPharmatech, San Diego
Background/Purpose: B-cell-activating factor (BAFF) plays a critical role in B cell survival, and its elevated expression can contribute to the presence of autoreactive B cells,…
Abstract Number: 0209 • ACR Convergence 2024
Characteristics of Ordering Providers and Patients with Positive Antinuclear Antibodies: A Pragmatic, Risk Model Study
Emily Grace, Sarah Green, Nikol Nikolova, Ashley Suh, Ryan Moore, Hank Domenico, Allison McCoy and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Positive antinuclear antibodies (ANAs) cause diagnostic dilemmas for clinicians across specialties. We previously developed and validated a risk model to predict risk of developing…
Abstract Number: 0308 • ACR Convergence 2024
Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases
Juan A. Meraz-Ostiz, Aina Puiggròs-Ferrer, Núria Bou, Irene Carrión-Barberà, Jordi Monfort, Carolina Pérez-García, Diana Badenes, Eva Balcells and Anna Pros-Simon, Hospital del Mar, Barcelona, Spain
Background/Purpose: Interstitial lung disease (ILD) is a common complication of connective tissue diseases (CTDs), significantly influencing prognosis and mortality. The prevalence and characteristics of new…
Abstract Number: 0452 • ACR Convergence 2024
Reproductive Health Needs of Women with Rheumatic Disease: An EMR-Based Online Survey Study
Krista Topalsky¹, Lindsay Frumker², Muhammad Shamim³, Omer Pamuk⁴, Jacqueline Colucci⁵ and Marina Magrey⁶, ¹University Hospitals/ Case Western Reserve University, Shaker Heights, OH, ²University hospitals Cleveland medical center, Highland Heights, OH, ³University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ⁵University Hospitals, Cleveland, OH, ⁶Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: Reproductive-aged women are disproportionately affected by rheumatologic disorders, making family planning issues like contraception, pre-conception counseling, fertility, pregnancy complications, and postpartum care critical components…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].